Hospitals sued CVS Health over alleged manipulation of 340B program savings through spread pricing, claiming diverted savings of roughly $250 million across 2020 to 2025. The plaintiffs include Mount Sinai, Michigan Medicine, and the University of Kansas Health System, framing the dispute as a practice that reduced the value of a federal safety-net drug program. Alongside that legal pressure, concurrent enforcement expectations around policy-adjacent systems and compliance remain salient for life sciences stakeholders who rely on stable reimbursement and channel behavior. The litigation may influence how pharmacy benefit managers structure pass-through savings and could drive broader scrutiny of 340B administration models. For biotech firms, the operational impact is indirect but real: program integrity affects patient access, net pricing expectations, and contracting negotiations with health systems and payers.